CD38 and Miyoshi myopathy: Sequential immunotherapies with CS1 CAR T cells and 225Ac CD38-TAT were chosen to increase the potency to toxicity ratio and to achieve a more durable remission by targeting two highly expressed MM antigens with different cytotoxic mechanisms.